The device is clinically proven and has regulatory
approvals to be marketed as a Class
1 medical device in Australia, Canada EEC,
Hong Kong, Japan, New Zealand, USA and
other countries. Patents have been granted
in those countries.
The aveoTSD can be prescribed to patients
via a dentist or medical physician, who can
also advise on problem snoring and its potentially
serious health consequences. This
advice may also include a visual anatomical
check to ensure the device !ts properly.
Users of the aveoTSD need one to three
days, occasionally more than two weeks, to
achieve compliance.